Announcement PDF Proposed issue of securities Update Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type Update to previous announcement Date of this announcement 5/1/2024 Reason for update to a previous announcement Proposed issue of securities approved by shareholders at EGM held 29 December 2023. Refer to next page for full details of the announcement Proposed issue of securities 1/8 Proposed issue of securities Part 1 - Entity and announcement details 1.1 Name of +Entity ALTERITY THERAPEUTICS LIMITED We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules. If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation). 1.2 Registered Number Type Registration Number ABN 37080699065 1.3 ASX issuer code ATH 1.4 The announcement is Update/amendment to previous announcement 1.4a Reason for update to a previous announcement Proposed issue of securities approved by shareholders at EGM held 29 December 2023. 1.4b Date of previous announcement to this update 22/11/2023 1.5 Date of this announcement 5/1/2024 1.6 The Proposed issue is: A placement or other type of issue Proposed issue of securities 2/8 Proposed issue of securities Part 7 - Details of proposed placement or other issue Part 7A - Conditions 7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis? Yes 7A.1a Conditions Approval/Condition Date for determination +Security holder approval 29/12/2023 Is the date estimated or actual? Actual Comments Part 7B - Issue details Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? Existing class Will the proposed issue of this +security include an offer of attaching +securities? Yes Details of +securities proposed to be issued ASX +security code and description ATH : ORDINARY FULLY PAID Number of +securities proposed to be issued 1,008,965,809 Offer price details Are the +securities proposed to be issued being issued for a cash consideration? Yes Proposed issue of securities 3/8 ** Approval received/condition met? Yes Proposed issue of securities In what currency is the cash consideration being paid? What is the issue price per +security? AUD - Australian Dollar AUD 0.00350 Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? Yes Attaching +Security Is the proposed attaching security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional +securities in a class that is already quoted or recorded by ASX)? New class Attaching +Security - New class (+securities in a class that is not yet quoted or recorded by ASX) Details of attaching +securities proposed to be issued ISIN Code (if Issuer is a foreign company and +securities are non CDIs) Have you received confirmation from ASX that the terms Will the entity be seeking quotation of the 'new' class of of the proposed +securities are appropriate and +securities on ASX? No equitable under listing rule 6.1? No ASX +security code +Security description New class-code to be confirmed Short-dated option +Security type Options Number of +securities proposed to be issued 1,371,428,571 Offer price details Are the +securities proposed to be issued being issued for a cash consideration? No Please describe the consideration being provided for the +securities One (1) free attaching short-dated option issued for each Placement share issued per Placement announcement 22 Nov 2023 Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities Proposed issue of securities 4/8 Proposed issue of securities Will all the +securities issued in this class rank equally in all respects from their issue date? Yes Options details +Security currency AUD - Australian Dollar Exercise price Expiry date AUD 0.0070 31/8/2024 Details of the type of +security that will be issued if the option is exercised ATH : ORDINARY FULLY PAID Number of securities that will be issued if the option is exercised One ATH fully paid ordinary share Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement. https://alteritytherapeutics.com/investor-overview/asx-announcements/ Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? New class Will the proposed issue of this +security include an offer of attaching +securities? No Details of +securities proposed to be issued ISIN Code (if Issuer is a foreign company and +securities are non CDIs) Have you received confirmation from Will the entity be seeking quotation ASX that the terms of the proposed of the 'new' class of +securities on +securities are appropriate and ASX? Yes equitable under listing rule 6.1? No ASX +security code +Security description New class-code to be confirmed Long-dated options +Security type Options Proposed issue of securities 5/8 Proposed issue of securities Number of +securities proposed to be issued 457,142,857 Offer price details Are the +securities proposed to be issued being issued for a cash consideration? No Please describe the consideration being provided for the +securities One (1) free attaching long-dated option issued for each three (3) Placement shares issued per Placement announcement 22Nov 2023 Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities Will all the +securities issued in this class rank equally in all respects from their issue date? Yes Options details +Security currency Exercise price Expiry date AUD - Australian Dollar AUD 0.0100 31/8/2026 Details of the type of +security that will be issued if the option is exercised ATH : ORDINARY FULLY PAID Number of securities that will be issued if the option is exercised One ATH fully paid ordinary share Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement. https://alteritytherapeutics.com/investor-overview/asx-announcements/ Part 7C - Timetable 7C.1 Proposed +issue date 8/1/2024 Proposed issue of securities 6/8 Proposed issue of securities Part 7D - Listing Rule requirements 7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? Yes 7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1 29/12/2023 7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? Yes 7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? No 7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? No Part 7E - Fees and expenses 7E.1 Will there be a lead manager or broker to the proposed issue? Yes 7E.1a Who is the lead manager/broker? MST Financial Services Pty Ltd 7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker? 6% of amount raised under Placement 7E.2 Is the proposed issue to be underwritten? No 7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue Part 7F - Further Information 7F.01 The purpose(s) for which the entity is issuing the securities The use of proceeds from this financing will provide ongoing funding of Alterity's Phase 2 clinical trials in MSA, planning for a Phase 3 clinical trial, continuing discovery and research efforts and general working capital. 7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? Proposed issue of securities 7/8 Proposed issue of securities 7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? No 7F.2 Any other information the entity wishes to provide about the proposed issue 7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of: The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f) Proposed issue of securities 8/8